World Congress on Cancers of the Skin 2018
17 August 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world. Coming together at the ICC in Sydney, it has been an insightful and educational Congress relating to skin cancer and melanoma.
A key feature evident throughout all presentations was the changing landscape relating to melanoma, and how far diagnosis, treatment and education have come. The exponential shift in melanoma survival rates over the last decade is reflective of the global melanoma research effort, however there remains much work still to be done.
Associate Professor Matt Carlino chaired the morning session, Local and Systemic Management of Advanced Melanoma, which included presentations on radiotherapy from Professor Angela Hong, and surgery from Associate Professor Robyn Saw and Professor John Thompson AO. Professor Thompson identified that while surgery has a changing place in melanoma treatment, it still cures 85% of Stage I & II disease. Surgery is not considered the preferred option for advanced melanoma patients, with immunotherapy and targeted therapy proving to be more effective.
Associate Professor Matt Carlino explained the issues surrounding targeted therapy and immunotherapy, and highlighted toxicity as one of the primary concerns of the treatments. The Congress was told, however, that these treatments are changing people’s lives and represent a huge step forward in increasing survival rates in advanced patients.
A key focus of the Congress was a session on Primary Prevention of Skin Cancer, where Dr Annika Smith and Associate Professor Anne Cust argued the importance of sunscreen and dispelled sunscreen myths citing accurate studies such as the ‘Primary Melanoma Project’, ‘The Vancouver Trial’, ‘The Nambour Trial’, as well randomised control trials. A key point emphasised was that use of sunscreen does not cause Vitamin D deficiencies. Delegates were advised that people should not deliberately expose themselves to the sun as incidental exposure is sufficient for Vitamin D levels. Sunscreen quantity and application were also highlighted as crucial.
Clinical Professor of Dermatology Darrell Rigel travelled from New York University Langone Medical Center to discuss US studies relating to sunscreen and melanoma prevention.
“The problem surrounding sunscreen application is simply that people aren’t using enough,” he said. Professor Rigel suggests that lack of cosmetic appeal is a major reason why people are avoiding sunscreen. “The best public health message is use a combination of protection; sunscreen and shade,” he said.
The afternoon session of Management of High Risk Early Stage Melanoma was chaired by Dr Alex Menzies and featured an entire MIA cohort with presentations from Professor Richard Scolyer, Professor Andrew Spillane, Dr Alexander Menzies and Professor Georgina Long.
Topics covered included staging guidelines, sentinel node biopsy, and adjuvant and neoadjuvant therapies. Professor Long emphasised the exciting time in the neoadjuvant therapy space with evidence suggesting drug therapy works better when a patient has an active tumour, rather than after the tumour has been surgically removed.
The WCCS has been an overwhelming success, with many brilliant minds banding together with the overall goal of better understanding skin cancer and melanoma, and ultimately better patient outcomes.
If you're a health professional and interested in taking your melanoma knowledge to the next level, check out our Melanoma Education Portal here.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.